NCT05204147View on ClinicalTrials.gov

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

July 21, 2026

Study Completion Date

July 21, 2026

Conditions
Advanced CancerMetastatic Cancer
Interventions
DRUG

Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A

Given IV

PROCEDURE

Biospecimen Collection

Correlative studies

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER